ANIP Share Price Performance
US$70.19
-28.62 (-28.96%)
37.7% undervalued intrinsic discount
US$112.71
Fair Value
Price US$70.19
AnalystConsensusTarget US$112.71
AnalystLowTarget US$91.00
AnalystHighTarget US$120.00
Fair ValueUS$112.71
Share Pricen/a
ANI Pharmaceuticals, Inc. Stock Price
- 3 Narratives written by author
- 1 Comments on narratives written by author
- 14 Fair Values set on narratives written by author
ANIP Community Narratives
AN
Fair Value
·Fair Value US$112.71 37.7% undervalued intrinsic discount
Expanding ACTH Potential And Rare Disease Markets Will Evolve
0users have liked this narrative
1users have commented on this narrative
4users have followed this narrative
AN
Fair Value
·Fair Value US$91 22.9% undervalued intrinsic discount
Pharmaceutical Pricing Pressures Will Erode Margins Amid Tighter Controls
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value
·Fair Value US$120 41.5% undervalued intrinsic discount
Emerging Markets And Aging Populations Will Expand Patient Access
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
ANI Pharmaceuticals
22.9% undervalued intrinsic discount
Pharmaceutical Pricing Pressures Will Erode Margins Amid Tighter Controls
View narrativeAN
Updated 17 Jul
ANI Pharmaceuticals
37.7% undervalued intrinsic discount
Expanding ACTH Potential And Rare Disease Markets Will Evolve
View narrativeAN
Updated 17 Jun
ANI Pharmaceuticals
41.5% undervalued intrinsic discount
Emerging Markets And Aging Populations Will Expand Patient Access
View narrativeAN
Published 17 Aug 2025
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
ANIP: Trial Progress And Capital Returns Will Support Balanced Long Run Outlook
Fair Value: US$91 22.9% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ANIP: Buyback And Stronger Cash Generation Will Support Future Earnings Power
Fair Value: US$112.71 37.7% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
Emerging Markets And Aging Populations Will Expand Patient Access
Fair Value: US$120 41.5% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
ANI Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- 4.65
- 60.40%
- 10.18%
- 102.2%
About ANIP
- Founded
- 2001
- Employees
- 970
- CEO
- WebsiteView website
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
